Top news of the week from Specialty Pharmacy Times.
The approvals of Delstrigo and Pifeltro are based on findings from 2 phase 3 clinical trials.
Medicare Part D plans will be given flexibility to tailor on-formulary drug coverage based on specific indications.
BAY94-9027 (Jivi) is approved for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older.
Cannabidiol treatment increased the production of inflammatory suppressor cells in mice, which reduced the clinical signs of MS.
Study highlights the importance of understanding, addressing, and bridging gaps in achieving viral suppression.
Top news of the day from across the health care landscape.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.